Introduction {#s1}
============

Vascular endothelial cells (ECs) develop unique cellular and molecular properties to meet the specialized needs of target tissues ([@bib4]; [@bib44]). In the central nervous system (CNS) vasculature, the object of study here, ECs acquire a set of properties that collectively form the blood-brain barrier (BBB) or its retinal equivalent, the blood-retina barrier (BRB). This unique EC phenotype arises from a genetic regulatory program that (1) suppresses the production of fenestrae- and caveolae-associated components, thereby reducing intra-endothelial diffusion and transcytosis, respectively, and (2) enhances the production of tight junction proteins that block intercellular diffusion, transporters that carry small molecules such as glucose and amino acids from the blood to the brain parenchyma, and efflux pumps that extrude toxic molecules from the brain parenchyma ([@bib72]).

Numerous studies have found that cultured ECs have a propensity to lose their tissue-specific properties ([@bib16]; [@bib18]; [@bib34]; [@bib51]; [@bib39]; [@bib10]; [@bib21]; [@bib31]; [@bib58]; [@bib62]; [@bib61]; [@bib71]; reviewed in [@bib25]). In the case of CNS ECs, overcoming this propensity is of both theoretical and practical interest. An EC culture system that could faithfully reproduce the small molecule permeability, transport, and extrusion properties of the BBB would permit high throughput in vitro screening of drug candidates to predict their brain penetration ([@bib25]). Loss of the CNS EC-specific expression profile by cultured brain ECs could result from a loss of brain-specific signaling, including beta-catenin signaling (also called canonical Wnt signaling). Conditional deletion of beta-catenin signaling components in ECs in vivo leads to loss of BBB-specific gene expression ([@bib37]; [@bib56]; [@bib15]; [@bib63]; [@bib73]; [@bib12]; [@bib27]). Conversely, elevating beta-catenin signaling in ECs in vivo leads to a partial conversion of highly permeable ECs in the circumventricular organs (CVOs) and choroid plexus to a BBB state ([@bib8]; [@bib64]).

Cultured ECs have traditionally been characterized by assessing their morphological and functional properties and by quantifying the abundances of a small number of marker proteins or transcripts. With the advent of NextGen sequencing technologies, it is now possible to profile the transcriptome and chromatin state on a genome-wide scale to obtain a comprehensive and quantitative view of cellular identity (e.g., [@bib22]; [@bib35]; [@bib49]). In the present study, we have characterized the effects of short-term in vitro culture on CNS EC identity at the level of the transcriptional and accessible chromatin landscapes. This analysis reveals both a rapid loss of BBB properties and resistance to the effects of beta-catenin stabilization during in vitro culture.

Results {#s2}
=======

Rapid loss of the CNS EC transcriptional signature upon culturing of primary brain ECs {#s2-1}
--------------------------------------------------------------------------------------

To acquire an unbiased, genome-wide view of the effect of in vitro culture on the transcriptional and chromatin landscapes of CNS ECs, we grew primary cultures of young adult (8--16 week) brain ECs in standard EC culture medium for eight days (see Materials and methods) and then performed RNA-seq and ATAC-seq on the resulting cells. To selectively culture brain ECs, we took advantage of the expression of P-glycoprotein -- an efflux pump with broad substrate specificity -- by CNS ECs but not by neurons, glia, or pericytes. Following dissociation of brain cells and enrichment for vascular fragments, the mixed culture was treated with puromycin for 2--2.5 days, which kills non-ECs and selectively spares ECs, a widely used method for preparing pure cultures of acutely isolated CNS ECs ([Figure 1A](#fig1){ref-type="fig"}; [@bib66]; [@bib2]; reviewed in [@bib25]). ECs were cultured on collagen-coated wells for eight days in 5% serum with supplementary growth factors (see Materials and methods). Immunostaining of the resulting EC cultures revealed uniform expression of the pan-EC marker CD31 (PECAM1) across the monolayer ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).

![RNA-seq reveals a rapid loss of the brain EC transcriptional signature during in vitro cell culture.\
(**A**) Schematic outline of the isolation, purification, and culture of brain ECs. (**B**) Scatter plots comparing cross-sample normalized RNA-seq read counts for all protein-coding genes (gray symbols) between acutely isolated adult brain ECs (y-axis; average of two independent samples) and primary brain ECs cultured for 8 days (x-axis; average of six independent samples). The left plot highlights (in red) EC-enriched genes that are expressed at similar levels in adult brain, P7 brain, P7 liver, P7 lung, and P7 kidney ECs. The right plot highlights (in blue) genes associated with the BBB (i.e., that are \>2 fold enriched in brain ECs relative to liver, lung, and kidney ECs). The majority of BBB genes show reduced expression in culture. (**C**) Heatmap depicting log~2~ transformed transcript abundances from cultured brain ECs, and from acutely isolated P7 and adult brain ECs, and P7 liver, lung, and kidney ECs for 993 tissue-specific EC genes. (**D**) Principal component analysis (PCA) based on the abundances of all protein-coding transcripts (top), EC-enriched transcripts (center), and pan-EC transcripts (i.e. transcripts common to adult brain, P7 brain, P7 liver, P7 lung, and P7 kidney ECs; bottom). The symbols for each sample represent biological replicates. Arrows indicate cultured EC data points. In the PCA in the bottom panel, the two samples in the upper right were replicates isolated by Method B, and their RNA-seq libraries were generated and sequenced by a different facility compared to the other four samples, which were isolated by method A (see Materials and methods). (**E**) Transcript abundances for six genes from each of the four indicated categories of transcripts. Labels at the bottom of the figure apply to all panels above.](elife-51276-fig1){#fig1}

We repeated the culture experiment three times, with cells from independent wells in each experiment serving as biological replicates for a total of six replicates for both RNA-seq and ATAC-seq ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Comparing the RNA-seq data for all protein-coding genes among the three independent experiments, the Pearson correlation ranged from 0.93 to 0.96 ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). An analogous comparison between two replicates of acutely isolated brain ECs (purified by FACS from the cerebrum and cerebellum of *Tie2-GFP* \[also known as *Tek-GFP*\] mice) gave a Pearson correlation of 0.93. \[The cerebrum EC data is new to this study; the cerebellum EC data were published previously ([@bib64]). For the present study, we combined the two EC data sets (cerebrum and cerebellum) to generate what we call 'adult brain ECs'.\] Comparisons within the paired replicates in the three cultured EC experiments gave a Pearson correlation of 0.99--1.00. In comparing acutely isolated versus cultured brain ECs, 3585 protein-coding transcripts met our criteria for differential expression (see Materials and methods): 1542 with a \> 2 fold increase in abundance in acutely isolated ECs and 2043 with a \> 2 fold increase in abundance in cultured ECs. Since some of the transcripts in the acutely isolated brain EC sample could have come from contaminating brain parenchymal cells, we restricted our analysis of transcripts enriched in this sample to a set of 1352 transcripts that were enriched \>2 fold in GFP+ cells (ECs) over GFP- cells (non-ECs, that is parenchymal cells) (see Materials and methods). Among these 1352 transcripts, 581 exhibited a \> 2 fold increase in abundance in acutely isolated ECs compared to cultured ECs. For a list of these genes, see [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

To more precisely define transcriptional changes in acutely isolated versus cultured brain ECs, we separately assessed abundance changes among pan-EC transcripts and among BBB transcripts ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We define pan-EC transcripts based on a \> 2 fold increase in abundance in ECs relative to parenchymal cells in adult brain and in four different EC subtypes analyzed at postnatal day (P)7 (brain, liver, lung, and kidney; [@bib49]) and on a lack of differential abundance (\<2 fold) among these EC subtypes. We define BBB transcripts based on a \> 2 fold increase in abundance in adult brain ECs compared to P7 liver, lung, and kidney ECs. Scatter plots comparing between-sample normalized RNA-seq read counts for acutely isolated versus cultured adult brain ECs show that, on average, pan-EC transcripts are present at similar levels, whereas most BBB transcripts show reduced abundance in the cultured brain ECs \[[Figure 1B](#fig1){ref-type="fig"}\]. This analysis indicates that, with eight days in culture, CNS ECs retain the core EC transcriptional program but begin losing the CNS-specific transcriptional program.

We next assessed the effect of in vitro culture on the expression of 993 genes that exhibit enriched expression in one or another of the four EC subtypes profiled at P7 (brain, liver, lung, and kidney) or in adult brain ('EC tissue-specific genes'; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). A dendrogram of the relatedness of the different EC samples shows that cultured adult brain ECs are more closely related to P7 and adult brain ECs than to P7 liver, lung, or kidney ECs ([Figure 1C](#fig1){ref-type="fig"}). The same pattern is observed if the analysis is expanded to all 4,557 EC-enriched genes ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Principal component analysis (PCA) of transcript abundances for all protein-coding genes shows substantial divergence of the cultured brain EC transcriptome compared to the in vivo brain, liver, lung, and kidney EC transcriptomes (upper panel of [Figure 1D](#fig1){ref-type="fig"}). This PCA also shows the close similarity of the P7 and adult in vivo brain EC transcriptomes. PCA of transcript abundances for all EC-enriched genes (middle panel of [Figure 1D](#fig1){ref-type="fig"}) and for pan-EC genes (bottom panel of [Figure 1D](#fig1){ref-type="fig"}) shows a similar divergence of the cultured brain EC transcriptome compared to the transcriptional profiles of the in vivo EC subtypes. In the bottom panel of [Figure 1D](#fig1){ref-type="fig"}, the upper right pair of cultured EC samples used a cell isolation protocol and RNA-seq pipeline that differed from those used for the four samples in the upper left, as described in the [Figure 1](#fig1){ref-type="fig"} legend and Materials and methods section.

In previous work ([@bib49]), single cell RNA-seq (scRNA-seq) of P7 brain ECs was used to define six major cell clusters: arterial, venous, mitotic, tip cell, and two capillary clusters, capillary-A and capillary-V; the latter two share some features with arterial and venous gene expression patterns, respectively. Using the top 500 transcripts enriched in each of the six scRNA-seq clusters, we compared expression levels between acutely isolated and cultured brain ECs ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). The cultured brain ECs showed reduced expression for some of the genes associated with the two capillary clusters ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, 'Capillary-A' and 'Capillary-V' panels), consistent with the BBB program manifesting primarily at the capillary level. The cultured brain ECs also show an increase in expression of several genes associated with the mitotic cluster, consistent with the proliferation of ECs in culture (red arrow in [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

To further explore the effect of in vitro culture on brain ECs, we analyzed the expression of different EC gene sets. As noted above, cultured brain ECs maintain relatively high-level expression of generic EC transcripts, although with some variability from sample-to-sample, and they exhibit reduced expression of BBB genes (181/279 are reduced \>2 fold; [Figure 1B](#fig1){ref-type="fig"} and [Figure 1E](#fig1){ref-type="fig"}). Genes known to be activated in response to beta-catenin signaling or whose protein products regulate beta-catenin signaling ([@bib6]; [@bib53]; [@bib11]; [@bib28]; [@bib40]) showed little or no expression in cultured brain ECs ([Figure 1E](#fig1){ref-type="fig"}), implying a lack of beta-catenin signaling under these culture conditions. We note that five of these genes -- *Apcdd1, Axin2, Lef1, Notum,* and *Spock2* -- also meet the criteria for inclusion as 'BBB genes', in accordance with the established role of beta-catenin signaling in CNS ECs. The abundances of six transcripts that are increased in cultured brain ECs compared to acutely isolated brain ECs are plotted in the last panel of [Figure 1E](#fig1){ref-type="fig"}.

We further examined the effect of in vitro culture on four categories of transcripts coding for BBB-associated proteins: (1) tight junction (TJ) proteins, (2) solute carrier family transporters, (3) ABC transporters, and (4) transcytosis-associated proteins ([@bib60]; [@bib49]; [@bib5]). These data are shown in [Figure 1---figure supplements 2B](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}, which also includes the transcriptome results for brain ECs cultured from mice with stabilized beta-catenin, as described below. Among the more abundant transcripts coding for TJ proteins there is a mixture of responses to in vitro culture: *Cldn5* transcripts show little change, *Lsr* and *Ocln* transcripts are reduced \~2 fold, *Jam2* and *Tjp1* transcripts are reduced \~5 fold, and *F11r* and *Tjp2* are elevated 2--4-fold in a subset of the cultured EC samples. Among transcripts coding for solute carrier family transporters, in vitro culture had either no effect (e.g., *Slc16a9*, *Slc1a1*, and *Slc46a3*) or it reduced expression, in several cases to a nearly undetectable levels (e.g., *Slc22a8*, *Slc38a3*, *Slc39a10*, and *Slco1c1*). The levels of multiple transcripts coding for ABC transporters are either unaffected (e.g., *Abcc4* and *Abcg2*) or elevated (e.g., *Abca3*, *Abcb1b*, *Abcc1*, and *Abce1*) by in vitro culture; the one exception is the most abundant isoform of P-glycoprotein (*Abcb1a*), which is greatly reduced by in vitro culture. Among transcytosis-associated transcripts, in vitro culture causes a dramatic reduction in the abundance of transcripts coding for the transcytosis regulator Mfsd2a ([Figure 1E](#fig1){ref-type="fig"}; [@bib7]) and concomitant increases in the abundances of transcripts coding for Caveolin-1, Caveolin-2, Cavin-1, Cavin-3, and Ehd2 (components of the Caveolin-mediated transcytotic pathway). Among 16 transcripts coding for proteins associated with Clathrin-mediated transcytosis, only *Clta* and *Cltb* show consistent elevation with in vitro culture.

In summary, the broad reduction in the expression of beta-catenin-responsive and BBB genes implies a reduction in beta-catenin signaling and the BBB gene expression program in brain ECs cultured in vitro.

Changes in accessible chromatin in cultured brain ECs reflect a loss of beta-catenin signaling {#s2-2}
----------------------------------------------------------------------------------------------

The identification of gene expression changes in cultured brain ECs implies corresponding changes in the chromatin landscape. Comparisons of accessible chromatin in acutely isolated versus cultured brain ECs show (1) loss of ATAC-seq peaks near multiple brain EC-specific genes that lose expression in cultured ECs, such as *Slco1c1* and *Mfsd2a*, and (2) gain of ATAC-seq peaks near multiple genes that are induced in cultured ECs, such as *Thbs1* and *Cyr61* (also known as *Ccn1*) ([Figure 2A](#fig2){ref-type="fig"}; the histograms in the genome browser images represent averages of the independent replicates). PCA of ATAC-seq read density at a consensus set of called ATAC-seq peaks indicates that the accessible chromatin landscapes of acutely isolated adult and P7 brain ECs are as different from cultured brain ECs as the latter is from peripheral ECs ([Figure 2B](#fig2){ref-type="fig"}). PCA also indicates that acutely isolated adult and P7 brain ECs have very similar accessible chromatin landscapes. Among 102,016 ATAC-seq peaks identified in the acutely isolated and cultured brain EC datasets, 16,760 were lost and 20,654 were gained as a result of in vitro culture ([Figure 2C](#fig2){ref-type="fig"}; [Supplementary file 2](#supp2){ref-type="supplementary-material"}).

![Changes in accessible chromatin, motif enrichment, and TF expression in primary brain ECs in culture.\
(**A**) Genome browser images showing ATAC-seq reads (top) and RNA-seq reads (bottom) at or near *Slco1c1* and *Mfsd2a*, BBB genes with reduced expression in cultured adult brain ECs (left panels), and *Thbs1* and *Cyr61* (*Ccn1*), genes with enhanced expression in cultured adult brain ECs (right panels). Increases in transcript abundance are accompanied by increases in accessible chromatin near each gene (black arrows). Read counts are averaged over the independent replicates ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). (**B**) PCA of ATAC-seq read density at all called ATAC-seq peaks in independent biological replicates from cultured adult brain ECs, acutely isolated adult and P7 brain ECs, and P7 liver, lung, and kidney ECs. Liver, lung, and kidney samples cluster at center right. The arrow points to cultured ECs. (**C**) Venn diagram summarizing the number of shared and distinct ATAC-seq peaks between acutely isolated and cultured adult brain ECs. (**D**) TF motif enrichment in ATAC-seq peaks that is specific to either acutely isolated adult brain ECs (left) or cultured adult brain ECs (right). Histograms of the -log~10~(p-value) for 414 TF DNA binding motifs that were tested for enrichment. The x-axis bin size is 1. The y-axis has been truncated. The vast majority of tested motifs have high p-values (i.e., low statistical significance) and thus are found in the first few bins. The statistically most significant TF motif families are labeled. Most TF families are represented by multiple closely related motifs, and only the motif with the lowest p-value for each family is labeled. The number of ATAC-seq peaks analyzed in (**D**) and (**E**) corresponds to the values shown in the Venn diagram in (**C**). (**E**) Enriched TF motifs identified by HOMER. The frequency of the indicated motifs is plotted as a function of distance from the center of the ATAC-seq peaks (from either acutely isolated or cultured adult brain ECs). Shown above each individual plot is the position weight matrix (PWM) of the enriched nucleotide sequence. The TF family that most closely matches the motif is indicated below the PWM. (**F**) Heatmap showing log~2~ transformed TPMs for acutely isolated and cultured adult brain ECs for transcripts coding for a subset of TFs with the motifs shown in (**E**).](elife-51276-fig2){#fig2}

Transcription factor (TF) motif enrichment analysis of ATAC-seq peaks revealed two distinctive trends: (1) accessible regions gained during in vitro culture were strongly enriched for motifs of the activator protein-1 (AP-1) complex (FOS, JUN, and ATF) and TEAD families, and (2) accessible regions lost during in vitro culture were strongly enriched for TCF/LEF, SOX, and SP/KLF motifs ([Figure 2D and E](#fig2){ref-type="fig"}). The AP1 and TEAD signatures in regions of gained open chromatin likely reflect cell proliferation and/or a stress response to the in vitro environment. The TCF/LEF signature in regions of open chromatin lost during in vitro culture likely reflects the loss of beta-catenin signaling under standard EC culture conditions. The SP/KLF signature in regions of open chromatin that are lost during in vitro culture could reflect the lack of laminar flow in our culture conditions, as both *Klf2* and *Klf4* expression in ECs is induced by laminar flow ([@bib3]). Both sets of accessible regions show similar enrichment for motifs of the ETS family of TFs, master regulators of EC development and function ([Figure 2D and E](#fig2){ref-type="fig"}; [@bib52]), consistent with the maintenance of general EC markers in culture.

Comparing the abundances of TF transcripts, [Figure 2F](#fig2){ref-type="fig"} shows that, relative to acutely isolated brain ECs, cultured brain ECs showed reductions in the abundances of transcripts for brain EC-enriched TFs *Lef1*, *Tcf7*, and *Zic3*, and increases in the abundances of transcripts for AP-1 family members *Fosl2* and *Jund* ([Figure 2F](#fig2){ref-type="fig"}). The down-regulation of transcripts coding for TFs such as *Lef1*, *Tcf7*, and *Zic3* that mediate beta-catenin signaling could be both a consequence and a cause of reduced signaling by this pathway.

Interestingly, transcripts coding for SP5, a direct target and downstream effector of beta-catenin signaling ([@bib65]; [@bib20]), are up-regulated in cultured ECs, whereas transcripts coding for SP1, a widely expressed TF that recognizes the same SP/KLF motif, are down-regulated (arrows in [Figure 2F](#fig2){ref-type="fig"}). Current evidence indicates that SP5 and its close homologue SP8 mediate many of the effects of Wnt3a signaling on neural and mesodermal development during mammalian gastrulation ([@bib17]; [@bib29]). In HEK293T cells and human pluripotent stem cells, SP5 acts as a beta-catenin-inducible transcriptional repressor to inhibit the expression of genes that are activated by SP1 ([@bib20]; [@bib26]), and Huggins and colleagues have proposed that SP5 acts in the termination phase of beta-catenin signaling to repress beta-catenin target genes. Pan-EC TF genes *Erg*, *Fli1*, and *Ets1* show minimal changes in expression in cultured brain ECs, consistent with the maintenance of general EC markers in culture.

Stabilization of beta-catenin does not promote a BBB-like state in cultured CNS ECs {#s2-3}
-----------------------------------------------------------------------------------

The data described thus far support the general inference from co-culture experiments with ECs and astrocytes, pericytes, and/or neurons that signals from the brain parenchyma are required to maintain the BBB state ([@bib25]). More specifically, the data are consistent with mouse genetic experiments showing that a neuronal- and/or glial-derived beta-catenin signal is necessary for BBB development and maintenance in vivo, as summarized in the Introduction. To explore this idea in the context of our short-term culture system, we used a genetic strategy to artificially activate beta-catenin signaling in ECs prior to in vitro culture. The strategy relies on Cre-mediated excision of exon 3 of the beta-catenin gene (*Ctnnb1*), which encompasses the sites of phosphorylation that lead to beta-catenin ubiquitination and degradation ([Figure 3A](#fig3){ref-type="fig"}; [@bib23]; the allele with *loxP* sites flanking exon 3 is referred to as *Ctnnb1^flex3^*). In previous work, Cre-mediated recombination of *Ctnnb1^flex3^* in ECs was induced in vivo using a *Pdgfb-CreER* transgene and intraperitoneal injection of 4-hydroxytamoxifen (4HT), a procedure that reliably produces \~80% efficient recombination, as determined by the partial conversion of CVO and choroid plexus ECs from a BBB-deficient to a BBB-proficient state ([@bib64]). In the present work, we have used the same mouse line and the same protocol as used for the CVO and choroid plexus conversion experiments, with CNS ECs harvested from *Ctnnb1^flex3^;Pdgfb-CreER;Tie2-GFP* mice 10 weeks after 4HT treatment.

![Stabilization of beta-catenin does not promote a BBB-like state in cultured CNS ECs as determined by RNA-seq and ATAC-seq.\
(**A**) Schematic outline of the genetic strategy for stabilizing beta-catenin (encoded by *Ctnnb1*). The *Ctnnb1^flex3^* allele contains *loxP* sites flanking exon 3. Cre-recombination produces an in-frame deletion of exon 3, and the resulting beta-catenin protein is stabilized and activates transcription in conjunction with LEF/TCF proteins. (**B**) Analysis of *Ctnnb1* transcripts that include or omit exon 3. The six replicates of wild-type (WT) cultured adult brain ECs produced no RNA-seq reads that join exons 2+4 whereas each of the four replicates of *Ctnnb1^flex3/+^;Pdgfb-CreER;Tie2-GFP* cultured adult brain ECs (in which exon 3 is deleted by Cre-mediated recombination) produced several hundred RNA-seq reads that join exons 2+4. (**C**) Scatter plots comparing cross-sample normalized RNA-seq read counts for protein-coding genes between beta-catenin stabilized and WT primary brain ECs cultured for 8 days. The left plot highlights (in red) EC-enriched genes that are expressed at similar levels in brain, liver, lung, and kidney EC subtypes. The right plot highlights (in blue) genes associated with the blood-brain barrier (BBB). Gene sets are as described for [Figure 1B](#fig1){ref-type="fig"}. Stabilizing beta-catenin does not increase the expression of BBB genes in cultured ECs. (**D**) Transcript abundances for seven genes from the 'Regulated by beta-catenin signaling' category. (**E**) PCA of protein-coding transcript abundances (RNA-seq; top) and PCA of ATAC-seq read density at all called ATAC-seq peaks (bottom) from independent biological replicates of WT and beta-catenin stabilized cultured adult brain ECs, acutely isolated adult and P7 brain ECs, and P7 liver, lung, and kidney ECs. The cyan-outlined red circles correspond to the beta-catenin stabilized cultured adult brain EC samples, and are indicated by cyan arrows. Black arrows point to cultured brain ECs without stabilized beta-catenin.](elife-51276-fig3){#fig3}

A comparison of RNA-seq read counts from brain ECs cultured from wild-type (WT) control (either C57BL/6J or *Ctnnb1^flex3/+^;Tie2-GFP*) injected with 100 ug 4HT at P10 and *Ctnnb1^flex3/+^;Pdgfb-CreER;Tie2-GFP* mice injected with 100 ug 4HT at P10 reveals reads spanning *Ctnnb1* exons 2+4 only in the genotype carrying the *Pdgfb-CreER* and *Ctnnb1^flex3^* alleles, implying that cultured brain ECs contain the exon 3 deleted transcripts that code for stabilized beta-catenin ([Figure 3A and B](#fig3){ref-type="fig"}). Similar ratios of *Ctnnb1* transcripts including or omitting exon 3 were observed in RNA-seq data sets obtained by [@bib64] from FACS-purified ECs from anterior and posterior pituitaries from control and *Ctnnb1^flex3/+^;Pdgfb-CreER;Tie2-GFP* mice ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Surprisingly, scatter plots comparing between-sample normalized RNA-seq read counts for WT versus beta-catenin stabilized cultured brain ECs show that expression of the exon 3 deleted allele of *Ctnnb1* had virtually no effect on the transcriptional profile of cultured brain ECs, and, in particular, had virtually no effect on either pan-EC transcripts or BBB transcripts ([Figure 3C](#fig3){ref-type="fig"}). Moreover, the expression of the six genes regulated by beta-catenin signaling that were shown in [Figure 1E](#fig1){ref-type="fig"}, and a seventh (*Tcf7*) were extremely low in beta-catenin stabilized cultured brain ECs ([Figure 3D](#fig3){ref-type="fig"}), implying a failure to activate beta-catenin signaling despite production of stabilized beta-catenin. PCA of transcript abundances for all protein-coding genes and PCA of all called ATAC-seq peaks also indicates that beta-catenin stabilized cultured brain ECs are virtually identical to their WT counterparts ([Figure 3E](#fig3){ref-type="fig"}, cyan and black arrows). The PCA analysis is consistent with visual inspection of the genomic alignments of RNA-seq and ATAC-seq reads ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) and with scatterplots of the abundances of transcripts coding for TJ proteins, solute carrier transporters, ABC transporters, and transcytosis proteins ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}). The simplest interpretation of these findings is that under the conventional in vitro culture conditions employed here, CNS ECs become refractory to the effects of beta-catenin stabilization.

Discussion {#s3}
==========

Organ-specific EC heterogeneity has been well-characterized at the morphological and functional levels, but the processes by which ECs are programmed to adopt organ-specific gene expression patterns remain largely unknown ([@bib1]; [@bib44]). In the case of CNS vascular development, neural tissue induces a BBB/BRB gene expression program in ECs that invade from the surrounding perineural vascular plexus ([@bib19]; [@bib57]). As noted in the Introduction, gene knockout studies in mice have demonstrated that an essential component of this BBB/BRB instructive signal is beta-catenin signaling, induced by neuron- and/or glia-derived ligands ([@bib37]; [@bib56]; [@bib15]; [@bib63]; [@bib73]; [@bib12]; [@bib8]; [@bib64]). Two additional pieces of evidence that underscore the central role of beta-catenin signaling in CNS EC-specific gene regulation are: (1) the presence in CNS ECs, but not in non-CNS ECs, of LEF1 and TCF7, members of the TCF/LEF family of transcription factors (TFs) that both mediate and are induced by the beta-catenin signal, and (2) enrichment of TCF/LEF binding motifs in brain EC-specific genomic regions with increased chromatin accessibility and reduced cytosine methylation, features associated with *cis*-regulatory elements ([@bib49]).

In short-term cultures of brain ECs, the present work reveals that the rapid reduction in the abundance of many BBB transcripts is correlated with reduced beta-catenin signaling. In contrast, the expression of generic EC genes, such as *Cd31/Pecam1*, is minimally affected. The reduction in beta-catenin signaling in culture is seen at both the transcriptional and chromatin accessibility levels. For example, multiple genes that are known beta-catenin targets and that are expressed in acutely isolated brain ECs are not detectably expressed or are expressed at extremely low levels in cultured brain ECs. Furthermore, while cultured brain ECs retain the expression of generic EC TF genes such as *Erg, Ets1,* and *Fli1*, the drastic reduction in expression of *Lef1* and *Tcf7*, which are both mediators and targets of beta-catenin signaling, likely contributes to the reduced response of cultured ECs to beta-catenin stabilization. One simple model for the difference between in vivo and in vitro patterns of gene expression is that under low beta-catenin signaling and no blood flow culture conditions, brain ECs utilize ETS family TFs in conjunction with AP1 and TEAD TFs to promote proliferation, whereas under the high beta-catenin signaling and normal blood flow conditions of the in vivo CNS, ETS TFs collaborate with SP/KLF, TCF/LEF, and ZIC factors to promote BBB gene expression. The lability of the BBB program in vitro is reminiscent of earlier experiments in which acute loss of EC beta-catenin signaling in vivo led to a loss of BBB markers and a loss of barrier integrity ([@bib37]; [@bib63]).

We note that the comparison between in vivo and cultured CNS ECs could conceivably be affected by the presence of GFP expression in the in vivo ECs and/or by the inclusion of a 2--2.5 day regimen of puromycin as part of the in vitro isolation procedure. We think the former is unlikely because, in the *Tie2-GFP* line, the GFP is unfused to other proteins and the level of GFP accumulation in ECs is low. We think that the latter is unlikely because following puromycin treatment ECs were cultured for an additional 5--6 days before they were harvested. We also note that the experiments reported here were carried under only a single culture condition: 5% bovine serum with a standard mixture of EC growth factors (see Materials and methods). The conditions used here are typical for CNS EC cultures ([@bib25]), and it would be interesting to determine the extent to which variations in percent serum and culture media can affect BBB-specific gene expression.

Based on the ability of stabilized beta-catenin to partially convert CVO and choroid plexus ECs to a BBB-like state ([@bib8]; [@bib64]), one might have expected that CNS ECs cultured from 4HT treated *Ctnnb1^flex3/+^;Pdgfb-CreER* mice would show a similar BBB-like transcriptional and chromatin accessibility state. However, as the experiments in [Figure 3](#fig3){ref-type="fig"} illustrate, the presence of a constitutively active form of beta-catenin has virtually no effect on the gene expression program of short-term cultured CNS ECs, and, in particular, it is unable to maintain the expression of BBB genes. Previous work with cultured brain ECs and with immortalized CNS EC lines has shown that activating beta-catenin signaling with Wnt ligands, small molecule agonists, or by genetic means can enhance the expression of genes specific to the BBB ([@bib42]). While our data appear to be at odds with the data of [@bib42], we note that Paollinelli and colleagues observed relatively modest effects of beta-catenin stabilization, and they did not include acutely isolated CNS ECs in their comparisons, leaving open the possibility that the transcriptional effects they observed were minor compared to the differences between in vivo and in vitro transcriptional programs.

Based on our genome-wide transcriptional and chromatin accessibility analyses, we suggest that one or more additional signaling pathways gate the beta-catenin signal in CNS ECs and that the relevant signals for these other pathways are missing from the in vitro culture system. If correct, this model implies that during normal development ECs encounter additional signals in the CNS that render them receptive to the beta-catenin signal. Whether these hypothesized signals include laminar blood flow and/or neural-specific molecules remain to be determined.

Finally, the present study serves as a demonstration of the utility of applying genome-wide transcriptional and chromatin accessibility profiling to the characterization of ECs in culture. This combination of approaches has been used previously to distinguish tumor and immune cell subtypes ([@bib14]; [@bib50]), and it should be useful in defining the differentiation state of CNS ECs grown under different culture or co-culture conditions or in the presence of candidate signaling molecules.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                      Designation                           Source or reference                                                                   Identifiers                                                                                Additional\
  (species) or resource                                                                                                                                                                                                                                     information
  ---------------------------------- ------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------
  Genetic reagent (*Mus musculus*)   *Ctnnb1^flex3^*                       DOI: [10.1093/emboj/18.21.5931](https://doi.org/10.1093/emboj/18.21.5931)                                                                                                        

  Genetic reagent (*M. musculus*)    *Tie2-Cre (Tek-Cre)*                  The Jackson Laboratory                                                                Stock No: 008863; RRID:[IMSR_JAX:008863](https://scicrunch.org/resolver/IMSR_JAX:008863)   

  Genetic reagent (*M. musculus*)    *Tie2-GFP (Tek-GFP)*                  The Jackson Laboratory                                                                Stock No: 003658; RRID:[IMSR_JAX:003658](https://scicrunch.org/resolver/IMSR_JAX:003658)   

  Genetic reagent (*M. musculus*)    *Pdgfb-CreER*                         DOI: [10.1002/dvg.20367](https://doi.org/10.1002/dvg.20367)                                                                                                                      

  Peptide, recombinant protein       Tn5 transposase                       Illumina                                                                              Cat no: FC-121--1030                                                                       

  Commercial assay or kit            Worthington Papain Dissociation Kit   Worthington Biochemical Corporation                                                   Cat no: LK003160                                                                           

  Chemical compound, drug            4-hydroxytamoxifen                    Sigma-Aldrich                                                                         Cat no: H7904                                                                              

  Software, algorithm                Salmon                                DOI: [10.1038/nmeth.4197](https://doi.org/10.1038/nmeth.4197)                                                                                                                    

  Software, algorithm                deepTools                             DOI: [10.1093/nar/gkw257](https://doi.org/10.1093/nar/gkw257)                         RRID:[SCR_016366](https://scicrunch.org/resolver/SCR_016366)                               

  Software, algorithm                tximport                              DOI: [10.12688/f1000research.7563.2](https://doi.org/10.12688/f1000research.7563.2)   RRID:[SCR_016752](https://scicrunch.org/resolver/SCR_016752)                               

  Software, algorithm                EBSeq                                 DOI: [10.1093/bioinformatics/btv193](https://doi.org/10.1093/bioinformatics/btv193)   RRID:[SCR_003526](https://scicrunch.org/resolver/SCR_003526)                               

  Software, algorithm                MACS2                                 DOI: [10.1186/gb-2008-9-9-r137](https://doi.org/10.1186/gb-2008-9-9-r137)                                                                                                        

  Software, algorithm                DiffBind                              DOI: [10.1038/nature10730](https://doi.org/10.1038/nature10730)                       RRID:[SCR_012918](https://scicrunch.org/resolver/SCR_012918)                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

The following mouse alleles were used: *Ctnnb1^flex3^* ([@bib23]); *Tie2-GFP* (also known as *Tek-GFP*; [@bib41]; JAX 003658); *Pdgfb-CreER* ([@bib13]); *Hprt^LSL-GFP^* ([@bib69]); *Tie2-Cre* (also known as *Tek-Cre*; [@bib32]; JAX 008863); and C57BL/6J (JAX 000664). For EC culture experiments, the mice consisted of control WT mice (either C57BL/6J or *Ctnnb1^flex3/+^;Tie2-GFP* that had received 100 ug 4HT at P10) and EC-specific beta-catenin stabilized mice (*Ctnnb1^flex3/+^;Pdgfb-CreER;Tie2-GFP* that had received 100 ug 4HT at P10). To control for the possibility of sex-dependent differences, male mice were used for all experiments. All mice were housed and handled according to the approved Institutional Animal Care and Use Committee (IACUC) protocol MO16M367 of the Johns Hopkins Medical Institutions.

Primary brain EC culture {#s4-2}
------------------------

Primary brain ECs were isolated and purified by either method A or method B, as described below. Both protocols take advantage of the specific expression of the multidrug efflux pump P-glycoprotein in brain ECs, which allows for positive selection using puromycin.

Method A was performed as previously described with slight modifications ([@bib66]). Briefly, brains were harvested from six mice at two months of age, minced with a razor blade, and digested in 5 ml of papain solution (20 units papain per ml; 1 mM L-cysteine; 0.5 mM EDTA; 100 units of DNase per ml) for one hour and ten minutes at 37° Celsius. Following enzymatic digestion, the tissue was gently triturated with a 10 ml pipet to break up vascular fragments from the brain parenchyma. The suspension was then mixed with 7 ml of 30% BSA solution and centrifuged at 1120 x g for 10 min at room temperature. Pelleted vascular fragments were washed once with 2 ml of EC growth medium (ECGM; EGM-2 MV, CC-3202, Lonza, Basel, Switzerland; components: hEGF, hydrocortisone, 5% fetal bovine serum, VEGF, hFGF-B, R^3^-IGF-1, ascorbic acid, and gentamicin and amphotericin-B replaced by penicillin and streptomycin), centrifuged at 300 x g for 5 min, resuspended in 8 ml of ECGM, and then distributed evenly into four collagen type one coated wells of a six-well plate. Cells were incubated at 37° Celsius overnight. The following morning, the cells were washed seven times with DMEM/F12 medium (12500--062, Thermo Fisher Scientific) and then placed in fresh ECGM. In the early evening, the media was replaced with ECGM plus puromycin (P8833-10MG, Sigma-Aldrich; 4 ug/ml) to kill non-ECs. Puromycin treatment was stopped after 2.5 days. Cells were cultured for eight days before harvesting for RNA-seq and ATAC-seq. Biological replicates consisted of cells from independent wells. To assess the purity of cultures achieved using this isolation protocol, we cultured brain ECs from *Tie2-Cre;Hprt^LSL-GFP^* ([@bib69]) mice expressing a nuclear-localized GFP in vascular ECs. Using the percentage of double GFP-positive and DAPI-positive nuclei as an assessment of EC purity, cultures exhibited \>98% purity.

Method B was performed as previously described with slight modifications ([@bib2]). Briefly, brains from 4 to 6 mice were placed in 5 mL of Dulbecco's PBS (DPBS) in a Dounce tissue grinder and homogenized (30 strokes with pestle A, and 25 strokes with pestle B). Following homogenization, 7 mL of 30% BSA solution was mixed with the homogenate. The mixture was then centrifuged for 10 min at 1120 x g at room temperature. After removal of the floating myelin layer and the BSA solution, the pelleted vascular fragments were resuspended in 10 mL of DMEM/F12 solution containing 1 mg/mL of STEMxyme collagenase/dispase (Worthington Biochemical, LS004106) and 4 ug/mL of DNase. The fragments were digested for 1 hr at 37° Celsius and then centrifuged at 440 x g for 5 min at room temperature. The digestion media was removed, and the cells were washed with 10 mL of warm DPBS. After another centrifugation at 440 x g for 5 min at room temperature, the pelleted cells were resuspended in an appropriate volume of ECGM supplemented with puromycin at 8 ug/mL in order to plate the cells at roughly 0.1 brains per cm^2^ of type one collagen-coated wells. Cells were incubated at 37° Celsius overnight, and the following day washed twice with DPBS. Fresh ECGM supplemented with puromycin was added, and the medium was changed the next day to puromycin-free ECGM.

Method A was used to generate RNA-seq WT and beta-catenin stabilized cultured brain EC replicates one and two as well as ATAC-seq WT cultured brain EC replicates one and two. Control cultured ECs processed by Method A were from C57BL/6J mice. Method B was used to generate RNA-seq WT cultured brain EC replicates three to six, RNA-seq beta-catenin stabilized cultured brain EC replicates three and four, ATAC-seq WT cultured brain EC replicates three to six, and ATAC-seq beta-catenin stabilized cultured brain EC replicates one and two. Control cultured ECs processed by Method B were from *Ctnnb1^flex3/+^;Tie2-GFP* mice.

Immunocytochemistry {#s4-3}
-------------------

ECs grown on coverslips were washed once with PBS and then fixed in 4% paraformaldehyde (PFA) for 15 min at room temperature. The following reagents were used: DAPI and rat anti-CD31 (1:300; 553370, BD BioSciences, San Jose, CA). Cells were incubated overnight with primary antibody diluted in 1x PBSTC (1x PBS + 1% Triton X-100 + 0.1 mM CaCl~2~) + 10% normal goat serum (NGS). Incubation and washing steps were performed at 4°C. Cells were washed at least three times with 1x PBSTC, and subsequently incubated overnight with a secondary antibody plus DAPI diluted in 1x PBSTC +10% NGS. Because a primary antibody raised in rat was used, secondary antibodies were additionally incubated with 1% normal mouse serum (NMS) as a blocking agent. The next day, cells were washed at least three times with 1x PBSTC, and mounted on a slide using Fluoromount G (EM Sciences 17984--25). Cells were imaged using a Zeiss LSM700 confocal microscope and processed with ImageJ.

4HT preparation and administration {#s4-4}
----------------------------------

Solid 4HT (Sigma-Aldrich H7904) was dissolved at 20 mg/ml in ethanol by extensive vortexing. Sunflower seed oil (Sigma-Aldrich S5007) was added to dilute the 4HT to 2 mg/ml and aliquots were stored at −80°C. Thawed aliquots were diluted with Sunflower seed oil to a final concentration of 1 mg/ml 4HT. All injections were performed intraperitoneally.

Acute isolation of adult brain ECs {#s4-5}
----------------------------------

Viable adult brain ECs were isolated from homozygous *Tie2-GFP* mice using the Worthington Papain Dissociation System (LK003160, Worthington Biochemical Corporation, Lakewood, NJ) and a MoFlo XDP Sorter (Beckman Coulter, Brea, CA) as previously described ([@bib49]), with propidium iodide negative cells considered as viable. To remove myelin from the dissociated brain, the suspension was mixed with 30% BSA solution (1:1 vol) and centrifuged at 1120 x g for 10 min at room temperature.

Sample processing for RNA-seq and ATAC-seq {#s4-6}
------------------------------------------

For acutely isolated ECs, RNA was extracted from GFP-positive and GFP-negative cells that were FACS sorted directly into QIAGEN Buffer RLT Plus and then processed using the RNeasy Micro Plus kit (74034, QIAGEN, Venlo, Netherlands). For cultured ECs, RNA was extracted by adding QIAGEN Buffer RLT Plus directly into the well followed by extraction using the RNeasy Micro Plus kit. For ATAC-seq, \~50,000 GFP-positive FACS-sorted cells or trypsinized cultured ECs were gently centrifuged and then resuspended in ice-cold lysis buffer (0.25 M sucrose, 25 mM KCl, 5 mM MgCl~2~, 20 mM Tricine-KOH, 0.1% Igepal CA-630) and immediately centrifuged at 500 x g for 10 min at 4°C to prepare nuclei. The resulting nuclear pellet was resuspended in a 50 ul reaction volume in Tn5 transposase and transposase reaction buffer (FC-121--1030, Illumina Inc, San Diego, CA), and the tagmentation reaction was incubated at 37°C for 30 min.

Library preparation and sequencing {#s4-7}
----------------------------------

Libraries for RNA-seq and ATAC-seq were prepared as previously described ([@bib9]; [@bib49]). Adult brain EC RNA-seq replicates were single-end sequenced for 75 cycles on a NextSeq500 (Illumina). WT cultured brain EC RNA-seq libraries for replicates one, two, five, and six and beta-catenin stabilized brain EC RNA-seq libraries for all four replicates were paired-end sequenced for 36 cycles on a NextSeq500. WT cultured brain EC RNA-seq libraries for replicates three and four were prepared by Omega Bioservices (Georgia) and paired-end sequenced for 150 cycles. Tagmented DNA was purified using QIAGEN MinElute Gel Extraction kit (28604, Qiagen). ATAC-seq libraries were PCR amplified for 11 cycles. Agencourt AMPure XP beads (A63880, Beckman Coulter) were used to purify ATAC-seq libraries, which were then paired-end sequenced for 36 cycles on a NextSeq500 (Illumina). Sequencing libraries that contained overrepresented adaptor sequences were trimmed using Trim Galore (<https://github.com/FelixKrueger/TrimGalore>).

Data analysis {#s4-8}
-------------

Most data analyses were performed as previously described ([@bib49]). For basic data processing, exploration, and visualization, we used deepTools ([@bib45]), the tidyverse collection of R packages ([@bib68]), ggplot2 ([@bib67]), and pheatmap ([@bib33]).

RNA-seq data analysis {#s4-9}
---------------------

Salmon version 0.14.0 ([@bib43]) was used to quantify expression of transcripts from RNA-seq experiments using GENCODE release M21 (`salmon quant -l A –validateMappings –mimicStrictBT2 --rangeFactorizationBins 4 --incompatPrior 0.0 --useVBOpt --seqBias --gcBias --posBias --biasSpeedSamp 10`). To visualize RNA-seq data on an IGV browser ([@bib47]; [@bib59]), HISAT2 version 2.1.0 ([@bib30]) was used to generate alignment bam files (`hisat2 --dta`) and then deepTools was used to generate bigwig files (`bamCoverage -bs 1 --normalizeUsing CPM`). To convert transcript-level abundances to the gene-level for further downstream analyses, we used tximport version 1.12.3 ([@bib54]).

Differentially expressed genes were identified using EBSeq version 1.24.0 ([@bib36]). A gene was considered to be differentially expressed if it met the following criteria: (1) a minimum two-fold enrichment between samples; (2) a posterior probability of differential expression (PPDE) greater than or equal to 0.95 \[PPDE = (1 - false discovery rate)\], that is an FDR \< 0.05; and (3) a TPM value greater than or equal to five in both biological replicates. To filter out background transcripts from surrounding parenchymal cells, a set of EC-enriched transcripts was determined for each tissue by comparing RNA-seq data from GFP-positive and GFP-negative sorted cells. A gene was considered EC-enriched if it met the following three criteria: (1) a minimum two-fold enrichment in GFP-positive compared to GFP-negative samples, (2) a PPDE greater than or equal to 0.95, and (3) relative expression greater than or equal to five transcripts per million (TPM) in both biological replicates. Principal component analysis was performed on variance stabilizing transformed data using the DESeq2 *vst* and *plotPCA* function ([@bib38]).

As described under 'Library preparation and sequencing', RNA samples were sequenced with paired-end 150 nt, single-end 75 nt, and paired-end 36 nt Illumina protocols. To test whether these different RNA-seq protocols affected genome alignment -- and, therefore, differential expression analysis -- we used the FASTX-Toolkit to trim the raw reads from one of the paired-end 150 nt samples to create two single-end 75 nt datasets, and a paired-end 36 nt data set (`fastx_trimmer -Q 33 l -z`). We then compared Salmon (version 0.14.0) quantification of gene expression from (1) the original 150 nt paired-end reads, (2) the trimmed 75 nt reads from one mate from the original pair, (2) the trimmed 75 nt reads of the other mate from each original pair, and (4) the trimmed 36 nt paired-end reads. Correlation coefficients for each of the four pair-wise comparisons were calculated, and the results show all four data sets were highly correlated with Pearson's r ranging from 0.994 to 0.998.

ATAC-seq data analysis {#s4-10}
----------------------

ATAC-seq data were aligned to the GRCm38 genome using HISAT2 version 2.1.0 (`hisat2 -t -X 2000 --no-mixed --no-discordant`) and then duplicate reads were removed (*picard MarkDuplicates*). Peaks were called using MACS2 version 2.1.2 (`callpeak -f BAM --nomodel --keep-dup all --shift −100 --extsize 200`) ([@bib70]). Peaks were then filtered for fold-change \>2 and -log(qvalue)\>2. deepTools was used to visualize ATAC-seq peaks on the browser (`bamCoverage -bs 1 –extendReads --ignoreDuplicates --normalizeUsing CPM`). To identify differential ATAC-seq peaks between acutely isolated and cultured adult brain ECs, DiffBind version 2.12.0 was used ([@bib55]; [@bib48]) with EdgeR ([@bib46]). For the comparison, DiffBind was used to develop a set of consensus peaks between replicates using the requirement that peaks must be in a minimum of two replicates (minOverlap = 2). To retrieve a set of high-confidence, cell type-enriched peaks, we filtered for peaks with an absolute fold difference \>2 and FDR \< 0.05. Principal component analysis was performed on 'regularized' log-transformed data using the DESeq2 *rlog* and *plotPCA* function. To identify transcription factor DNA binding motifs enriched in ATAC-seq peaks, the HOMER suite of tools was used for motif discovery ([@bib24]), in particular, `findMotifsGenome.pl -size given. AnnotatePeaks.pl -m -size 1000 -hist` 5 was used to generate histograms of enriched motifs.
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###### Gene expression data.

(**A**) EC-enriched transcripts for adult brain. PPDE, posterior probability of differential expression (1-FDR). (**B**) Differentially expressed genes in acutely isolated adult brain ECs when compared to cultured brain ECs. (**C**) The intersection of genes in (A) and (B). EC-enriched differentially expressed genes in acutely isolated adult brain ECs. (**D**) Differentially expressed genes in cultured brain ECs when compared to acutely isolated adult brain ECs. (**E**) All EC-enriched genes. (**F**) Pan-endothelial cell genes. (**G**) Tissue-specific EC genes. (**H**) Blood-brain barrier genes. (**I**) Blood-brain barrier genes with reduced expression in cultured brain ECs.

###### Accessible chromatin peaks.

(**A**) Differential ATAC-seq peaks in acutely isolated adult brain ECs when compared to cultured brain ECs. (**B**) Differential ATAC-seq peaks in cultured brain ECs when compared to acutely isolated adult brain ECs.

Data availability {#s7}
=================

Sequencing data have been deposited in GEO under accession code GSE118731.

The following dataset was generated:

SabbaghMFNathansJ2019A genome-wide view of the de-differentiation of central nervous system endothelial cells in cultureNCBI Gene Expression OmnibusGSE118731

The following previously published datasets were used:

SabbaghMFHengJLuoCCastanonRGNeryJRRattnerAGoffLAEckerJRNathansJ2018Transcriptional and Epigenomic Landscapes of CNS and non-CNS Vascular Endothelial CellsNCBI Gene Expression OmnibusGSE111839

WangYSabbaghMFGuXRattnerAWilliamsJNathansJ2019The role of beta-catenin signaling in regulating barrier vs. non-barrier gene expression programs in circumventricular organ and ocular vasculaturesNCBI Gene Expression OmnibusGSE111839

10.7554/eLife.51276.sa1

Decision letter

Bautch

Victoria L

Reviewing Editor

University of North Carolina, Chapel Hill

United States

Cleuren

Audrey

Reviewer

University of Michigan

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

We believe that this Research Advance describing epigenetic and transcriptional changes to vascular endothelial cells isolated from the central nervous system and cultured in vitro adds to the original study of freshly isolated CNS endothelial cells (Sabbagh et al., 2018). It is also interesting that forced expression of b-catenin that partially restores CNS patterns in vivo does not appear to be effective in vitro.

**Decision letter after peer review:**

Thank you for submitting your article \"A genome-wide view of the de-differentiation of central nervous system endothelial cells in culture\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Didier Stainier as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Audrey Cleuren (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This Research Advance compares the transcriptional and epigenetic landscapes of freshly isolated brain ECs versus cultured brain ECs. Data indicate loss of BBB-associated transcripts in brain ECs cultured in vitro, coincident with downregulation of the β-catenin signaling pathway. ECs with artificially activated β-catenin signaling prior to culturing were evaluated, hypothesizing that this would result in a better representation of the in vivo BBB EC phenotype. While stabilized β-catenin transcript levels are present in vitro, RNA-seq and ATAC-seq data show virtually no effect on profiles from wild-type versus mutant mice. Overall, the data presented illustrate the phenotypic drift brain ECs undergo during in vitro culture, which is particularly relevant for the evaluation and extrapolation of in vitro studies.

Essential revisions:

To bolster the presented results and increase the rigor of the study, two follow up experiments and one additional comparison and clarification are indicated:

1\) The acutely isolated EC are homozygous for Tie2-GFP, while the cultured EC are isolated from WT mice and puromycin selection. A formal comparison of GFP+ sorted cells and EC directly after puromycin selection would help address differences due to isolation protocol vs. culture. This would also address potential differential selection of ECs due to use of different concentrations of puromycin in different experiments.

2\) The lack of induction in Wnt responsive genes suggest that either some signals present in the CNS are missing, or alternatively that signals derived from the serum present in the EC medium may block function of activated β-catenin. TGF β signaling is highly induced by serum. Therefore, performing these experiments under culture conditions with very low serum (0.5%) in the absence and presence of TGFbeta inhibitors would better test if Wnt downstream targets are induced in culture.

3\) In vitro experiments performed with brain ECs originating from Ctnnb1flex3/+ mice do not show substantial differences in transcriptional profiles as compared to ECs derived from wild-type mice, whereas previous work using these mice from Wang et al. (*eLife* 2019;8:e43257) demonstrated partial conversion from permeable ECs to a barrier-type state in vivo. The current study shows that after culturing, transcripts representing the stabilized β-catenin form are present, although appear to make up \<50% of all transcripts (Figure 1---figure supplement 1B). It would be of interest to compare in vitro data to the previous in vivo data in Wang et al., particularly to see if there are more stable transcripts present in vivo and assess possibility of selection bias towards the wild-type (non-stabilized) allele when performing the EC isolation and culture.

4\) It is not always clear which data are new and which represent reanalysis of data already reported in the authors\' previous paper on which this report is based. For example, are the data from the acutely isolated brain ECs the same data already reported in the original manuscript? If so, this should be directly acknowledged/referenced in the current report.

10.7554/eLife.51276.sa2

Author response

> Essential revisions:
>
> To bolster the presented results and increase the rigor of the study, two follow up experiments and one additional comparison and clarification are indicated:
>
> 1\) The acutely isolated EC are homozygous for Tie2-GFP, while the cultured EC are isolated from WT mice and puromycin selection. A formal comparison of GFP+ sorted cells and EC directly after puromycin selection would help address differences due to isolation protocol vs. culture. This would also address potential differential selection of ECs due to use of different concentrations of puromycin in different experiments.

With respect to the first sentence, while we have not formally ruled out an effect of GFP expression from Tie2-GFP on endothelial cell (EC) properties, we note that the level of GFP expression in the Tie2-GFP line is quite low; the GFP fluorescence is sufficient for detection by FACS, but to visualize the GFP signal by confocal microscopy in tissue sections we must use anti-GFP immunostaining (unlike other mouse lines such as mTmG, that have strong GFP or tdTomato expression). Moreover, the GFP in the Tie2-GFP line is unmodified so that it accumulates diffusely in the cell. Unlike histone-GFP fusions, free monomeric GFP is relatively benign. For these two reasons we think it highly unlikely that the presence of GFP in the Tie2-GFP line is altering the gene expression pattern of CNS ECs. With respect to the third sentence ("different concentrations of puromycin"), we think it is a strength of the present study that we explored minor variations on the puromycin protocol (one with 4 ug/ml puromycin and the other with 8 ug/ml puromycin) and obtained very similar results.

The goal of the present study was to assess the effect of a brief period of in vitro culture on CNS EC gene expression and chromatin state using the standard protocol for CNS EC isolation. The 8 days between cell isolation and harvesting for RNAseq and ATACseq is about as short an interval as is practical because one needs 2 days of puromycin treatment to kill non-endothelial cells (ECs) and a few more days to completely remove dying cells and obtain sufficient numbers of brain ECs to do the "omics" analyses. The yield of vascular fragments, from which the ECs emerge, is quite low -- typically the vascular fragments from an entire adult mouse brain are sufficient for only one well of a 6-well plate and generate several tens of thousands viable ECs.

In response to this comment, we have tried purifying and culturing brain ECs using FACS sorting of GFP+ cells from the Tie2-GFP line (and thereby omitting the puromycin treatment), but almost no ECs obtained by this method survive in culture, most likely because ECs are highly sensitive to the mechanical trauma associated with FACS. For more than a decade, nearly all laboratories that have cultured acutely isolated brain ECs have used the protocols that we used, i.e. starting with vascular fragments purified by low speed centrifugation followed by puromycin selection to eliminate non-ECs.

> 2\) The lack of induction in Wnt responsive genes suggest that either some signals present in the CNS are missing, or alternatively that signals derived from the serum present in the EC medium may block function of activated β-catenin. TGF β signaling is highly induced by serum. Therefore, performing these experiments under culture conditions with very low serum (0.5%) in the absence and presence of TGFbeta inhibitors would better test if Wnt downstream targets are induced in culture.

The culture conditions that we have used, and, in particular, our use of 5% serum and EC supplements, are representative of the standard culture conditions for CNS ECs in experiments aimed at studying BBB properties in vitro. As evidence of this statement, we have collated the% serum used in CNS EC cultures as reported in ten papers chosen at random from the review by Helms et al., 2016, which summarizes the present state of CNS EC culture conditions that are used to promote BBB properties. The ten references (including, in some cases, the original reference with the detailed protocol) and% serum are listed below. The% serum for EC culture ranges from 2% to 20%, with the majority using 10% or 20% serum.

The goal of the present study is not to explore variations in culture conditions that might make the cultured ECs more or less BBB-like, but to make a detailed and rigorous genome-wide assessment of the state of gene expression under the conditions for CNS EC culture that are the standard in the field. With regard to investigating the effect of lowering serum from 10% to 0.5%, as suggested above, this might prove interesting but it also may not be physiologic, since ECs in vivo are bathed (on one side) in 100% serum. In our view, a mechanistic analysis of the TGF-β signaling pathway (or other pathways that potentially intersect with the Wnt pathway) as beyond the scope of the present study.

11-10-2019 table of serum% for EC culture systems

Reference numbers are from the following review:

Helms HC, Abbott NJ, Burek M, Cecchelli R, Couraud PO, Deli MA, Förster C, Galla HJ, Romero IA, Shusta EV, Stebbins MJ, Vandenhaute E, Weksler B, Brodin B.

in vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016 May;36(5):862-90.

20% bovine serum (ref 96)

N. Perrière, P. Demeuse, E. Garcia, A. Regina, M. Debray, J.P. Andreux, P. Couvreur, J.M. Scherrmann, J. Temsamani, P.O. Couraud, M.A. Deli, F. Roux. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood--brain barrier-specific properties.J. Neurochem., 93 (2005), pp. 279-289

Perrière N, Yousif S, Cazaubon S, Chaverot N, Bourasset F, Cisternino S, Declèves X, Hori S, Terasaki T, Deli M, Scherrmann JM, Temsamani J, Roux F, Couraud PO.

A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 2007 May 30;1150:1-13.

10% serum (ref 98)

Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.Neurochem Int. 2009 Mar-Apr;54(3-4):253-63.

10% FBS (ref 99)

Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, Tsuruo T, Sawada Y, Niwa M, Kataoka Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-β production. Brain Res. 2005 Mar 21;1038(2):208-15.

2.5% FBS (ref 103)

Hatherell K1, Couraud PO, Romero IA, Weksler B, Pilkington GJ. Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods. 2011 Aug 15;199(2):223-9.

Weksler BB1, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005 Nov;19(13):1872-4.

20% FBS (ref 109)

Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, Morissette C, Fenart L, Cecchelli R, Tremblay P, Dehouck B. Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab Invest. 2005 Jun;85(6):734-46.

2% FCS (ref 110)

Förster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J, Drenckhahn D. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol. 2005 Jun 1;565(Pt 2):475-86.
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> 3\) In vitro experiments performed with brain ECs originating from Ctnnb1flex3/+ mice do not show substantial differences in transcriptional profiles as compared to ECs derived from wild-type mice, whereas previous work using these mice from Wang et al. (eLife 2019;8:e43257) demonstrated partial conversion from permeable ECs to a barrier-type state in vivo. The current study shows that after culturing, transcripts representing the stabilized β-catenin form are present, although appear to make up \<50% of all transcripts (Figure 1---figure supplement 1B). It would be of interest to compare in vitro data to the previous in vivo data in Wang et al., particularly to see if there are more stable transcripts present in vivo and assess possibility of selection bias towards the wild-type (non-stabilized) allele when performing the EC isolation and culture.

Just to clarify: the statement above that "Wang et al. (*eLife* 2019;8:e43257) demonstrated partial conversion from permeable ECs to a barrier-type state in vivo" refers specifically to vasculature in the circumventricular organs (CVOs) and the choroid plexus, those exceptional CNS vascular beds with highly permeable capillaries. Here we are studying ECs from the conventional brain vasculature, which has a BBB. In ECs that comprise the BBB+ brain vasculature, β-catenin is already stabilized to some extent by Wnt signaling, and further stabilization of β-catenin in vivo (by deleting exon 3) has only a minimal effect on gene expression, as demonstrated in Wang et al., 2019.

Comparing the fraction of Ctnnb1 transcripts from the in vivo experiments that have or do not have exon 3 is a good idea. We have now quantified the abundances of Ctnnb1 transcripts from the Wang et al., 2019, in vivo RNAseq data sets, representing FACS purified anterior and posterior pituitary ECs with or without Pdgfb-CreER mediated excision of Ctnnb1 exon 3 from the floxed allele. These data are now plotted in a new Figure 3---figure supplement 2. These data, like the data from the cultured ECs in the present study, show RNAseq reads spanning Ctnnb1 exons 2+4 (i.e. missing exon 3) only in Pdgfb-CreER;Ctnnb1flex3 mice that were treated with 4-hydroxytamoxifen (4HT). The in vivo data from Wang et al., 2019 show that, on average, \~25% of Ctnnb1 transcripts in the FACS sorted pituitary ECs are missing exon 3, as determined from the ratio of RNAseq reads spanning exons 2+4 compared to exons 2+3. With an estimated \~80% efficiency of CreER-mediated excision (as judged by the fraction of ECs that convert their immunostaining patterns) and only one of the two alleles carrying a floxed exon 3, we would expect \~40% of Ctnnb1 transcripts to be missing exon 3. In the present study, the cultured ECs obtained from the same mouse line, and treated in the same manner with 4HT, showed that, on average, \~40% of Ctnnb1 transcripts are missing exon 3 (Figure 3B). we note that the in vivo data from purified pituitary ECs shows more variability, most likely reflecting limited read coverage in that region of the Ctnnb1 mRNA. Our assessment is that, within experimental error, the in vivo (\~25%) and in vitro (\~40%) data are similar. This is now noted in the Results section.

> 4\) It is not always clear which data are new and which represent reanalysis of data already reported in the authors\' previous paper on which this report is based. For example, are the data from the acutely isolated brain ECs the same data already reported in the original manuscript? If so, this should be directly acknowledged/referenced in the current report.

Thank you for alerting us to this issue, which we have now clarified in the text. In this manuscript, adult brain ECs refers to combined data from adult cerebrum and cerebellum. The following data is new: ATACseq and RNAseq on ECs in culture and on ECs acutely isolated from adult cerebrum. The ATACseq and RNAseq from adult cerebellum were reported in Wang et al., 2019 and the P7 brain, liver, lung, and kidney ATACseq and RNAseq data were described in Sabbagh et al., 2018. The P7 brain EC single-cell RNA-seq was described in Sabbagh et al., 2018. This is now clarified in the Results and Materials and methods sections.
